© doodlartdotcom/pixabay.com

ERS Genomics and Cellular Engineering Technologies collaborating

ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.

Read more
© CureVac AG

Boehringer walks away from CureVac deal

Setback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company.

Read more
© Valneva

New vaccine trial targets Covid variants

Vaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001.

Read more
© zehra soy/ Pixabay.com

Visus Therapeutics cashes in €20m from LSP

Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia 

Read more
© Karolinska Institutet

Protein may help control cancer cells

The protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find.

Read more
Mission Therapeutics is specialised in identifying disiease-relevant DUBs and DUB inhibitors. © Mission Therapeutics

British drug developer Mission Therapeutics plc earns $20m milestone

British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.

Read more
Source: Bayer AG

Bayer takes over Vividion

The big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.

Read more
© Spectricity

Spectricity raises €14m in Series B round

Belgian semiconductor specialist Spectricity BV has baged €14m  to speed up the development of mobile hyperspectral sensors for medical applications.

Read more
Paul Hudson, CEO of Sanofi. © Sanofi

Sanofi snaps up mRNA partner for US$3.2bn

Sanofi further launches into the messenger RNA space with US$3.2bn buy-out of mRNA pioneer Translate Bio.

Read more